Metformin and Other Biguanides in Oncology: Advancing the Research Agenda

Overview

Journal Cancer Prev Res (Phila)

Specialty Oncology

Date 2010 Sep 3

PMID 20810670

Citations 104

Authors

Michael Pollak

Affiliations

Soon will be listed here.

Abstract

Retrospective studies that may be impractical to confirm prospectively suggest that diabetics treated with metformin have a substantially reduced cancer burden compared with other diabetics. It is unclear if this reflects a chemopreventive effect, an effect on transformed cells, or both. It also remains to be established if these data have relevance to people without diabetes. Laboratory models, however, provide independent impressive evidence for the activity of metformin and other biguanides in both cancer treatment and chemoprevention. Investigations of mechanisms of action of biguanides have revealed considerable complexity and have identified important gaps in knowledge that should be addressed to ensure the optimal design of clinical trials of these agents. Such trials may define important new indications for biguanides in the prevention and/or treatment of many common cancers.

Citing Articles

Effects of Biguanide-PROTACs in Pancreatic Cancer Cells.

Vatte J, Bourdeau V, Ferbeyre G, Schmitzer A Molecules. 2024; 29(22).

PMID: 39598718 PMC: 11596947. DOI: 10.3390/molecules29225329.

Chemopreventive and Biological Strategies in the Management of Oral Potentially Malignant and Malignant Disorders.

Viglianisi G, Polizzi A, Grippaudo C, Cocuzza S, Leonardi R, Isola G Bioengineering (Basel). 2024; 11(1).

PMID: 38247942 PMC: 10813134. DOI: 10.3390/bioengineering11010065.

Pharmacophore mapping approach to find anti-cancer phytochemicals with metformin-like activities against transforming growth factor (TGF)-beta receptor I kinase: An in silico study.

Reza R, Morshed N, Samdani M, Reza M PLoS One. 2023; 18(11):e0288208.

PMID: 37943796 PMC: 10635513. DOI: 10.1371/journal.pone.0288208.

Incidence, risk factors, and management of alpelisib-associated hyperglycemia in metastatic breast cancer.

Shen S, Chen Y, Carpio A, Chang C, Iyengar N Cancer. 2023; 129(24):3854-3861.

PMID: 37743730 PMC: 10863751. DOI: 10.1002/cncr.34928.

The Emerging Role of Metformin in the Treatment of Hepatocellular Carcinoma: Is There Any Value in Repurposing Metformin for HCC Immunotherapy?.

Papadakos S, Ferraro D, Carbone G, Frampton A, Vennarecci G, Kykalos S Cancers (Basel). 2023; 15(12).

PMID: 37370771 PMC: 10295995. DOI: 10.3390/cancers15123161.

References

Foretz M, Hebrard S, Leclerc J, Zarrinpashneh E, Soty M, Mithieux G . Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. J Clin Invest. 2010; 120(7):2355-69. PMC: 2898585. DOI: 10.1172/JCI40671. View

Engelman J, Cantley L . Chemoprevention meets glucose control. Cancer Prev Res (Phila). 2010; 3(9):1049-52. DOI: 10.1158/1940-6207.CAPR-10-0178. View

Gwinn D, Shackelford D, Egan D, Mihaylova M, Mery A, Vasquez D . AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol Cell. 2008; 30(2):214-26. PMC: 2674027. DOI: 10.1016/j.molcel.2008.03.003. View

Wu R, Zhao J, Jin H, Shao P, Fang M, Guo X . Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial. JAMA. 2008; 299(2):185-93. DOI: 10.1001/jama.2007.56-b. View

Minokoshi Y, Alquier T, Furukawa N, Kim Y, Lee A, Xue B . AMP-kinase regulates food intake by responding to hormonal and nutrient signals in the hypothalamus. Nature. 2004; 428(6982):569-74. DOI: 10.1038/nature02440. View

Shackelford D, Shaw R . The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. Nat Rev Cancer. 2009; 9(8):563-75. PMC: 2756045. DOI: 10.1038/nrc2676. View

Bodmer M, Meier C, Krahenbuhl S, Jick S, Meier C . Long-term metformin use is associated with decreased risk of breast cancer. Diabetes Care. 2010; 33(6):1304-8. PMC: 2875444. DOI: 10.2337/dc09-1791. View

Kalaany N, Sabatini D . Tumours with PI3K activation are resistant to dietary restriction. Nature. 2009; 458(7239):725-31. PMC: 2692085. DOI: 10.1038/nature07782. View

Phoenix K, Vumbaca F, Fox M, Evans R, Claffey K . Dietary energy availability affects primary and metastatic breast cancer and metformin efficacy. Breast Cancer Res Treat. 2010; 123(2):333-44. PMC: 2888909. DOI: 10.1007/s10549-009-0647-z. View

10.

Bolen S, Feldman L, Vassy J, Wilson L, Yeh H, Marinopoulos S . Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med. 2007; 147(6):386-99. DOI: 10.7326/0003-4819-147-6-200709180-00178. View

11.

Cool B, Zinker B, Chiou W, Kifle L, Cao N, Perham M . Identification and characterization of a small molecule AMPK activator that treats key components of type 2 diabetes and the metabolic syndrome. Cell Metab. 2006; 3(6):403-16. DOI: 10.1016/j.cmet.2006.05.005. View

12.

Shu Y, Sheardown S, Brown C, Owen R, Zhang S, Castro R . Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Invest. 2007; 117(5):1422-31. PMC: 1857259. DOI: 10.1172/JCI30558. View

13.

Smith M, Lee H, Nathan D . Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab. 2006; 91(4):1305-8. DOI: 10.1210/jc.2005-2507. View

14.

Pollak M . Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer. 2008; 8(12):915-28. DOI: 10.1038/nrc2536. View

15.

Anisimov V, Egormin P, Bershtein L, Zabezhinskii M, Piskunova T, Popovich I . Metformin decelerates aging and development of mammary tumors in HER-2/neu transgenic mice. Bull Exp Biol Med. 2005; 139(6):721-3. DOI: 10.1007/s10517-005-0389-9. View

16.

Hosono K, Endo H, Takahashi H, Sugiyama M, Uchiyama T, Suzuki K . Metformin suppresses azoxymethane-induced colorectal aberrant crypt foci by activating AMP-activated protein kinase. Mol Carcinog. 2010; 49(7):662-71. DOI: 10.1002/mc.20637. View

17.

Law J, Habibi G, Hu K, Masoudi H, Wang M, Stratford A . Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival. Cancer Res. 2008; 68(24):10238-46. DOI: 10.1158/0008-5472.CAN-08-2755. View

18.

Algire C, Amrein L, Zakikhani M, Panasci L, Pollak M . Metformin blocks the stimulative effect of a high-energy diet on colon carcinoma growth in vivo and is associated with reduced expression of fatty acid synthase. Endocr Relat Cancer. 2010; 17(2):351-60. DOI: 10.1677/ERC-09-0252. View

19.

Zakikhani M, Dowling R, Sonenberg N, Pollak M . The effects of adiponectin and metformin on prostate and colon neoplasia involve activation of AMP-activated protein kinase. Cancer Prev Res (Phila). 2009; 1(5):369-75. DOI: 10.1158/1940-6207.CAPR-08-0081. View

20.

Huang X, Wullschleger S, Shpiro N, McGuire V, Sakamoto K, Woods Y . Important role of the LKB1-AMPK pathway in suppressing tumorigenesis in PTEN-deficient mice. Biochem J. 2008; 412(2):211-21. DOI: 10.1042/BJ20080557. View